Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorena Landuzzi

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Plos One|January 7, 2014
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugCecilia Garofalo, Mariantonietta Capristo, Maria Cristina Manara, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2009
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cellsLaura Menotti, Giordano Nicoletti, Valentina Gatta, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 27, 2002
HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cellsCinzia Ricci, Letizia Polito, Patrizia Nanni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2006
Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine roleArianna Palladini, Annalisa Astolfi, Stefania Croci, et al.
Cancers|April 14, 2019
Cancer Vaccines Co-Targeting HER2/Neu and IGF1RCarla De Giovanni, Lorena Landuzzi, Arianna Palladini, et al.
Cell Communication and Signaling : CCS|October 11, 2024
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Cancer Research|June 5, 2003
Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant micePatrizia Nanni, Giordano Nicoletti, Carla De Giovanni, et al.
Oncoimmunology|September 18, 2018
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesisPatrizia Nanni, Carla De Giovanni, Alessia Burocchi, et al.
Journal of Cell Communication and Signaling|November 11, 2024
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscapeMichela Pasello, Maria Antonella Laginestra, Maria Cristina Manara, et al.
Cancer Research|November 19, 2004
Immunological prevention of a multigene cancer syndromeStefania Croci, Giordano Nicoletti, Lorena Landuzzi, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Plos One|January 7, 2014
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugCecilia Garofalo, Mariantonietta Capristo, Maria Cristina Manara, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2009
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cellsLaura Menotti, Giordano Nicoletti, Valentina Gatta, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 27, 2002
HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cellsCinzia Ricci, Letizia Polito, Patrizia Nanni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2006
Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine roleArianna Palladini, Annalisa Astolfi, Stefania Croci, et al.
Cancers|April 14, 2019
Cancer Vaccines Co-Targeting HER2/Neu and IGF1RCarla De Giovanni, Lorena Landuzzi, Arianna Palladini, et al.
Cell Communication and Signaling : CCS|October 11, 2024
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Cancer Research|June 5, 2003
Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant micePatrizia Nanni, Giordano Nicoletti, Carla De Giovanni, et al.
Oncoimmunology|September 18, 2018
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesisPatrizia Nanni, Carla De Giovanni, Alessia Burocchi, et al.
Journal of Cell Communication and Signaling|November 11, 2024
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscapeMichela Pasello, Maria Antonella Laginestra, Maria Cristina Manara, et al.
Cancer Research|November 19, 2004
Immunological prevention of a multigene cancer syndromeStefania Croci, Giordano Nicoletti, Lorena Landuzzi, et al.
Pageof 9